Squarepoint
TEVA icon

Squarepoint’s Teva Pharmaceuticals TEVA Stock Holding History

Squarepoint’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Sell
7,400
-494,900
-99% -$16.5M ﹤0.01% 3935
2026
Q1 		$15.1M Sell
502,300
-516,700
-51% -$16.6M 0.02% 848
2025
Q4 		$31.8M Buy
1,019,000
+214,200
+27% +$5.28M 0.03% 560
2025
Q3 		$16.3M Buy
804,800
+341,600
+74% +$6M 0.02% 847
2025
Q2 		$7.76M Sell
463,200
-189,800
-29% -$3.06M 0.01% 1208
2025
Q1 		$10M Buy
653,000
+75,900
+13% +$1.36M 0.01% 1025
2024
Q4 		$12.7M Buy
577,100
+482,000
+507% +$8.77M 0.01% 1009
2024
Q3 		$1.71M Buy
+95,100
New +$1.66M ﹤0.01% 2179

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Squarepoint's TEVA Position: Q2 2026 in Review

Squarepoint reduced its Teva Pharmaceuticals (TEVA) stake by 66% in Q2 2026, selling an estimated $3.66M and leaving 57,807 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Squarepoint first reported a position in TEVA in Q3 2017 and has held it in 26 quarters since. The position peaked at $10.2M in Q1 2025. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Squarepoint held 57,807 shares of Teva Pharmaceuticals worth $1.96M as of Q2 2026.
  • Squarepoint sold 109,773 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.66M.
  • Teva Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2356 holding.
  • Squarepoint first reported a position in Teva Pharmaceuticals in Q3 2017 and has held it in 26 quarters since.
  • Squarepoint's Teva Pharmaceuticals position peaked at $10.2M in Q1 2025.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.